Pharmaceutical companies cannot find and develop skilled workers fast enough to support domestic manufacturing expansion

U.S. pharma companies are reshoring manufacturing operations but face a critical talent shortage that's blocking their ability to scale production. Current workforce development approaches are fragmented and slow, failing to produce the specialized technicians, engineers, and operators needed for new domestic facilities. This bottleneck is delaying multi-billion dollar reshoring investments and threatening supply chain resilience.